Curis Inc
CRIS1.615USD
-0.015-0.92%
Horário de mercado （ET）Cotações atrasadas em 15 min
16.90MValor de mercado
PerdaP/L TTM
Mais detalhes de Curis Inc Empresa
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). Its other clinical programs include Fimepinostat and CA-170. Fimepinostat is an oral, dual inhibitor of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3K) enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target V-domain Ig Suppressor of T-cell Activation (VISTA) and PDL1 immune checkpoint proteins.
Informações da empresa
Código da empresaCRIS
Nome da EmpresaCuris Inc
Data de listagemAug 01, 2000
CEOMr. James E. Dentzer
Número de funcionários33
Tipo de títulosOrdinary Share
Fim do ano fiscalAug 01
Endereço128 Spring Street
CidadeLEXINGTON
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal02421
Telefone16175036500
Sitehttps://www.curis.com/
Código da empresaCRIS
Data de listagemAug 01, 2000
CEOMr. James E. Dentzer
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. James E. Dentzer
Mr. James E. Dentzer
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
8.39K
+37.97%
Ms. Diantha Duvall
Ms. Diantha Duvall
Chief Financial Officer
Chief Financial Officer
4.90K
+660.71%
Dr. Kenneth I. Kaitin, Ph.D.
Dr. Kenneth I. Kaitin, Ph.D.
Independent Director
Independent Director
1.41K
--
Mr. Martyn D. Greenacre
Mr. Martyn D. Greenacre
Independent Chairman of the Board
Independent Chairman of the Board
1.30K
--
Dr. Jonathan Zung, Ph.D.
Dr. Jonathan Zung, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Dr. Anne Borgman, M.D.
Dr. Anne Borgman, M.D.
Independent Director
Independent Director
--
--
Dr. John A. Hohneker, M.D.
Dr. John A. Hohneker, M.D.
Independent Director
Independent Director
--
--
Dr. Marc Rubin, M.D.
Dr. Marc Rubin, M.D.
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. James E. Dentzer
Mr. James E. Dentzer
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
8.39K
+37.97%
Ms. Diantha Duvall
Ms. Diantha Duvall
Chief Financial Officer
Chief Financial Officer
4.90K
+660.71%
Dr. Kenneth I. Kaitin, Ph.D.
Dr. Kenneth I. Kaitin, Ph.D.
Independent Director
Independent Director
1.41K
--
Mr. Martyn D. Greenacre
Mr. Martyn D. Greenacre
Independent Chairman of the Board
Independent Chairman of the Board
1.30K
--
Dr. Jonathan Zung, Ph.D.
Dr. Jonathan Zung, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Dr. Anne Borgman, M.D.
Dr. Anne Borgman, M.D.
Independent Director
Independent Director
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 17 de mai
Atualizado em: sáb, 17 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Bleichroeder LP
8.63%
Armistice Capital LLC
8.61%
Satterfield (Thomas A Jr)
7.39%
Maverick Capital, Ltd.
5.26%
M28 Capital Management LP
4.34%
Other
65.76%
Investidores
Investidores
Proporção
Bleichroeder LP
8.63%
Armistice Capital LLC
8.61%
Satterfield (Thomas A Jr)
7.39%
Maverick Capital, Ltd.
5.26%
M28 Capital Management LP
4.34%
Other
65.76%
Tipos de investidores
Investidores
Proporção
Investment Advisor
18.74%
Hedge Fund
16.28%
Individual Investor
7.53%
Venture Capital
1.66%
Investment Advisor/Hedge Fund
1.46%
Research Firm
0.78%
Other
53.54%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
101
5.57M
46.46%
+1.30M
2025Q1
112
5.58M
53.29%
+1.28M
2024Q4
119
3.88M
45.77%
+849.35K
2024Q3
129
2.03M
33.69%
-831.36K
2024Q2
151
2.33M
39.45%
-531.00K
2024Q1
226
2.12M
35.82%
-1.17M
2023Q4
249
2.07M
35.17%
-1.64M
2023Q3
265
2.42M
42.19%
-1.36M
2023Q2
279
1.78M
36.08%
-2.05M
2023Q1
312
1.73M
35.82%
-2.73M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Bleichroeder LP
1.04M
8.63%
+515.12K
+98.96%
Mar 31, 2025
Armistice Capital LLC
1.03M
8.61%
+957.37K
+1259.69%
Mar 31, 2025
Satterfield (Thomas A Jr)
886.71K
7.39%
+274.49K
+44.84%
Mar 31, 2025
Maverick Capital, Ltd.
631.83K
5.26%
--
--
Mar 31, 2025
M28 Capital Management LP
521.06K
4.34%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
303.19K
2.53%
+32.94K
+12.19%
Mar 31, 2025
CM Management, LLC
240.00K
2%
+20.00K
+9.09%
Mar 31, 2025
Alyeska Investment Group, L.P.
189.38K
1.58%
-8.84K
-4.46%
Mar 31, 2025
Samsara BioCapital, LLC
185.94K
1.55%
-12.27K
-6.19%
Mar 31, 2025
Renaissance Technologies LLC
96.87K
0.81%
+2.80K
+2.98%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
iShares Micro-Cap ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
Proporção0%
Avantis US Small Cap Equity ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sep 28, 2023
Merger
20<1
Sep 28, 2023
Merger
20<1
Sep 28, 2023
Merger
20<1
Sep 28, 2023
Merger
20<1
Data
Tipo
Proporção
Sep 28, 2023
Merger
20<1
Sep 28, 2023
Merger
20<1
Sep 28, 2023
Merger
20<1
Sep 28, 2023
Merger
20<1
